10.02.2011 • News

Sanofi CEO Says Genzyme Offer May Be Extended

Sanofi Aventis Chief Executive Chris Viehbacher said in an interview that the French pharmaceuticals group's offer for Genzyme could be extended for a third time, beyond the Feb. 15 deadline.

Asked by La Tribune newspaper about the deadline, Viehbacher said: "It is a possibility, there are no limits on takeover offers in the United States."

He added: "It is normal to spend time on an operation of $18.5 billion."

Viehbacher's interview is to be published in La Tribune business newspaper on Thursday and was made available late on Wednesday.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Top-Feature

most read